Of the 155 individual biopharmaceutical products approved, 81 52% were genuinely new to the market, with the remaining products representing biosimilars, metoo. It is an exciting time for biosimilars, with many approvals and drugs being brought to market in the us in the past several years and more poised to follow suit as patents expire. As per the report global biosimilar market outlook 2022, the global biosimilars market is anticipated to witness a high double digit growth during 20162022. The oncology segment is dominating the global market for biosimilars in terms of revenue owing to the high prevalence of cancer including lung, liver, colorectal, stomach, breast, and blood cancer. Inhouse manufacturing of the biosimilar products helps the companies to monitor and assess every step on the production and reduces other costs of delivery and shipping. Postapproval market surveillance with same name for biosimilars works for identification.
Biosimilar mabs expanding the global biosimilar market. Biosimilars manufacturers would of course prefer that biological products were prescribed by inn allows for possible substitution in the future enables biosimilars to grab a bigger market share. Based on route of administration roa, the biosimilars market is categorized into intravenous, subcutaneous, intranasal, and others. Biosimilars market by product analysis recombinant. Monoclonal antibodies mabs, fusion proteins, insulin, erythropoietins, granulocyte colonystimulating factor gcsf, interferons, growth hormones, fertility hormones our new study shows you revenue prospects for biosimilars and followon biologics at total world, submarket and national levels to 2021.
The first anticancer mab biosimilars were approved in europe in 2017 29,30. Yet many challenges remain around the growth of a robust biosimilars market. Currently, it is anticipated that a faster approval pace and a healthy pipeline will contribute to market growth while more biosimilars and other drug forms e. Global market for biosimilars by drug class, through 2021 table 12. The increase in preferences for local producers will require fulltime participation by international companies in cooperative partnerships with the russian companies. The increasingly human and profitable monoclonal antibody.
The monoclonal antibody mab market has changed rapidly in the past 5 years. By type of manufacturing, the inhouse manufacturing segment accounted for the largest market share in 2019. Global biosimilar market outlook 2022 research and markets. Biosimilars market size, share, growth forecast report, 2026. Although it has been constantly growing since 2007, by 2010 biosimilars have only a 15% market share of the aggregate products market. The genericdrugs market segment reported the highest growth in. This report focuses on top manufacturers in global. A number of companies are focusing on monoclonal antibodies \mab\ for their role in cancer therapy. The iqvia report showed a firstmover advantage for biosimilars in 2016 in the eu, with the first followon generally claiming the biggest share of the biosimilar market. Indian companies have launched biosimilars across product areas, but certain product types remain more attractive entry opportunities. This report studies mab biosimilars in global market, especially in north america, china, europe, southeast asia, japan and india, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022. This report provides a detailed analysis of the current and future market scenario of the global biosimilars market. Biosimilars market growth, trends, and forecast 20192024. Biosimilars market size, share industry analysis and.
Biosimilars market size, share, trends, growth and. As of early 2019, there are 7 biosimilar products that have launched in the united states us, and many more are on the horizon. Winning with biosimilars opportunities in global markets while most players will want a presence. Sep 05, 2019 super market research via comtex according to the recent report by imarc group, the global biosimilar market size was. Winning with biosimilars opportunities in global markets deloitte. Forecast from 2016 2026 of the 17 biosimilar mabs in the market.
Costeffectiveness of biosimilar drugs and high prevalence of chronic disorders globally are some major factors contributing to market growth. Once biosimilar mabs start to invade their market, however, the scenario will change dramatically. Biopharmaceutical medicines represent a growing share of the. An analysis of the us biosimilars development pipeline and likely market evolution by ronald a. Biosimilars, also known as subsequent entry biologics sebs or followon biologics, refer to fdaapproved biotherapeutic products which are similar to their reference biologics.
World market prospects 202023 biosimilar rituximab will expand at a cagr of. Biosimilars market compared with biologics, through 2021 table 12. Monoclonal antibodies mabs market is estimated to be usd 148. Biopharmaceutical benchmarks 2018 nature biotechnology. The correlation between biosimilar volume market share of the total market and price. Global biosimilars and followon biologics market 20192029.
Asean and china biosimilars market size, share analysis 2025. Based on the type of manufacturing, the biosimilars market is segmented into inhouse manufacturing and contract manufacturing. Global biosimilar monoclonal antibodies mabs market 2020. However, firstgeneration biosimilars like gcsf and epo have continued to garner increasing market share since 2010.
Global monoclonal antibodies mabs biosimilars market. Our reports on biosimilar monoclonal antibodies mabs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering. The global biosimilars market size was valued at usd 4. Biosimilars and nonoriginal biologics are likely to take 410% market share by. Global mab biosimilars market 2017 industry research report. Currently mabs hold the lions share of the biologic market sales, and remain the largest technology class within the biologic pipeline. Biosimilars market size by product recombinant nonglycosylated proteins human.
Product identification of retacrit epoetin zeta and nivestim filgrastim postmarket records created from dec. Monoclonal antibodies key to unlocking the biosimilars market. The impact of biosimilar competition in europe european. Biosimilars market analysis global share outlook report. Emerging biosimilars market presents opportunities and.
On average across europe in 2016, the first biosimilar tnf inhibitor launched took 70% by volume of the total antitnf biosimilar market. Biosimilars administered through intravenous route occupied the largest market share, of 48. We summarize the market in terms of therapeutic applications, type and structure of mabs, dominant companies, manufacturing locations, and emerging markets. With this growth comes the continued need to reinforce with key stakeholders the potential benefits that biosimilars will bring to the us healthcare market. Barriers to the market access of biosimilar monoclonal. Dna technology, monoclonal antibodies technology industry analysis report, regional. Get more details on this report request free sample pdf.
This report also provides the growth prospects for the market during the forecast period. Only then, biosimilar mabs will be able to fully live up to their costsaving potential. According to the national cancer institute nci report, it was estimated that 1,735,350 new cases of cancer are diagnosed in the us in 2018, and. In conclusion, barriers to the market access of biosimilar mabs could be reduced when more transparency and communicationeducation is used in all steps toward market access in order to increase trust in biosimilar mabs by all stakeholders. Global biosimilars and followon biologics market 2019.
Geographical segmentation of the global biosimilars market classified the market as north america, europe, asia, and rest of the world. The biosimilars market, many analysts believe, is on the cusp of significant growth. A large share of t\ he market is expected from mabs in the future biosimilars marketplace. Mabs and antibody fragments 145 91 cancertargeted proteins non mab 264 159. An analysis of the us biosimilars development pipeline and. Biosimilar monoclonal antibodies market forecast 20162026. Biologics market to expand at a significant cagr of 6. Europe was the largest regional market for biosimilars in 2019. Prescribing by brand requires much more intensive marketing by biosimilars.
Overcoming barriers to the market access of biosimilars in the european union. Biosanapharma making the biosimilar market biogeneric. Biosimilars market followonbiologics by types human growth hormone, erythropoietin, monoclonal antibodies, insulin, interferon, granulocytecolony. The four biosimilar market leaders and their market shares, 20082014. Biosimilars market scenario, biosimilars market size is expected to register a cagr of 7. A large share of the market is expected from mabs in the future.
Monoclonal antibodies mabs market is segmented by product type fully human, murine, chimeric, humanized, drug types branded biologics, biosimilars and region. The biosimilars industry was solely concentrated in the european market since 2006 when the first biosimilar was approved in the. Opportunities and challenges in biosimilar development. Inhouse manufacturing of biosimilars held around 75% market share in the year 2018 and was valued at usd 7,843. An analysis of the us biosimilars development pipeline and likely. Electronic pdf the global monoclonal antibodies mabs market was valued at usd 85. Biosimilars market global biosimilars industry size, share, growth, analysis, research and forecast report, 2014 to 2024 global biosimilars market size was valued at 3. The case of biosimilar monoclonal antibodies article pdf available in frontiers in pharmacology 7suppl.
Russia aims to boost its domestic pharmaceutical industry and increase its market share by 50% in 2020 from 20% in 2012. A biosimilar can be developed only after the patent expiry of the original product according to the report, one driver that will lead to the growth of this market is the rise in number of patent. Market for biosimilars by geography, through 2021 table 12. Profiles of 10 leading companies either with biosimilar mabs already on the market or in the pipeline in addition to new merger and acquisition analysis. The limited existing evidence suggests, however, that the relative rates of market share uptake and impact on prices are much lower for biological medicines than for smallmolecule medicines. Biosimilars market size, share, trends, report, 2024. But emergence of biosimilars owing to the patent expiration of various drugs can threaten the market growth. The mab biosimilars market shows a strong growth potential, due to government support and current and imminent patent expiry of blockbuster mab biologics. Monoclonal antibody antineoplastic agents use monoclonal antibodies. Monoclonal antibodies mabs market size, share industry. Biosimilars market analysis global share outlook report 20192025. This report focuses on monoclonal antibodies mabs biosimilars volume and value at global level, regional level and company level.